EAS Consensus Lowers Age and LDL-C Targets for Pediatric FH
This consensus statement recalibrates diagnostic thresholds, treatment initiation age, and LDL-C goals for children with familial hypercholesterolaemia, expanding the pharmacist's role in early lipid-lowering therapy.
Early FH detection in children can extend life expectancy.
Early diagnosis and treatment of familial hypercholesterolaemia (FH) in children can significantly improve life expectancy and reduce the risk of premature cardiovascular disease. Revised diagnostic criteria and treatment goals for LDL cholesterol (LDL-C) in children with FH are presented, emphasizing early screening and initiation of lipid-lowering therapies (LLTs). The guideline highlights the need for pediatric FH screening programs and updated LDL-C treatment goals, which can enhance early intervention strategies. Implementing pediatric FH screening and early LLT can drastically improve long-term outcomes.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Wiegman A, Bourbon M, Freiberger T, Gidding SS, Greber-Platzer S, Groselj U, Holven KB, Hudgins LC, Humphries SE, Hutten BA, Ibarretxe D, Pederiva C, Peretti N, Raal FJ, Ramaswami U, Sanin V, Santos RD, Steinhagen-Thiessen E, Watts GF, Perkins R, Benn M, Binder CJ, Romeo S, Roeters van Lennep JE
Citation:Wiegman A, Bourbon M, Freiberger T, et al. Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement. European heart journal. 2026;47(26):3324-3346. doi:10.1093/eurheartj/ehag382